한글목차

암 단클론항체 시장 규모는 2025년 1,318억 5,000만 달러에서 2026년부터 2034년까지 CAGR 18.87%로 성장하여 2034년에는 6,247억 9,000만 달러에 달할 것으로 예측됩니다.

암 발병률 증가와 표적 치료제에 대한 수요 증가를 배경으로 암 단클론항체 시장은 괄목할 만한 성장세를 보이고 있습니다. 단클론항체(mAbs)는 암세포를 특이적으로 표적하도록 설계된 인공 단백질로, 기존 화학요법에 비해 보다 정밀한 치료 옵션을 제공합니다. 의료진과 환자들이 효과적이고 독성이 적은 치료법을 찾는 가운데, 암 단클론항체 수요는 증가할 것으로 예상되며, 이 시장은 견조한 성장이 예상됩니다. 현재 치료법에는 트라스투주맙, 리툭시맙과 같은 기존 mAbs와 함께 다양한 암종을 표적으로 하는 새로운 약물이 포함됩니다.

또한, 단클론항체 기술의 발전은 시장 내 혁신을 주도하고 있습니다. 이중특이성항체, 항체약물접합체, 면역관문억제제의 개발은 치료 효과와 특이성을 높여 암 치료에 혁명을 일으키고 있습니다. 이러한 혁신은 치료 결과를 개선할 뿐만 아니라 부작용을 최소화하고 환자의 전반적인 삶의 질(QOL)을 개선합니다. 단클론항체의 새로운 적용과 병용요법에 대한 연구가 진행됨에 따라 치료 옵션의 개선이 기대됨에 따라 시장은 더욱 확대될 것으로 예상됩니다.

또한, 맞춤형 의료에 대한 관심이 높아지면서 암 단클론항체 분야가 형성되고 있습니다. 의료진들이 유전적, 분자적 특성에 기반한 개별 환자 프로파일에 맞춘 치료의 중요성을 점점 더 인식함에 따라, 맞춤형 치료 전략에 따른 mAb(단클론항체)에 대한 수요가 증가할 것으로 예상됩니다. 이러한 추세는 특정 바이오마커가 적절한 단클론항체 치료제의 선택을 유도하는 동반진단의 맥락에서 특히 중요합니다. 암 단클론항체 시장이 계속 진화하고 있는 가운데, 혁신적인 치료법 조합, 맞춤의료에 대한 관심, 그리고 지속적인 연구가 향후 성장을 견인하는 데 중요한 역할을 할 것으로 보입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 암 단클론항체 시장 : 유형별

제5장 세계의 암 단클론항체 시장 : 용도별

제6장 세계의 암 단클론항체 시장 : 최종사용자별

제7장 세계의 암 단클론항체 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Cancer Monoclonal Antibodies Market size is expected to reach USD 624.79 Billion in 2034 from USD 131.85 Billion (2025) growing at a CAGR of 18.87% during 2026-2034.

The cancer monoclonal antibodies market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Monoclonal antibodies (mAbs) are engineered proteins designed to specifically target cancer cells, offering a more precise treatment option compared to traditional chemotherapy. As healthcare providers and patients seek effective and less toxic treatment alternatives, the demand for cancer monoclonal antibodies is expected to rise, positioning this market for robust expansion. Current therapies include well-established mAbs such as trastuzumab and rituximab, as well as newer agents that target various cancer types.

Moreover, advancements in monoclonal antibody technology are propelling innovation within the market. The development of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors is revolutionizing cancer treatment by enhancing the efficacy and specificity of therapies. These innovations not only improve treatment outcomes but also minimize side effects, thereby improving the overall quality of life for patients. As research continues to explore new applications and combinations of monoclonal antibodies, the market is likely to expand further, driven by the promise of improved therapeutic options.

Additionally, the growing emphasis on personalized medicine is shaping the cancer monoclonal antibodies landscape. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient profiles based on genetic and molecular characteristics, the demand for mAbs that align with personalized treatment strategies is likely to rise. This trend is particularly relevant in the context of companion diagnostics, where specific biomarkers guide the selection of appropriate monoclonal antibody therapies. As the cancer monoclonal antibodies market continues to evolve, the combination of innovative therapies, a focus on personalized care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Humanized
• Human
• Chimeric
• Murine

By Application

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

By End-user

• Hospitals
• Research Institutes
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Bristol Myers Squibb Co, Merck Co, GlaxoSmithKline plc, Johnson Johnson, Amgen Inc, Novartis AG, AstraZeneca plc, Eli Lilly and Company, AbbVie

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER MONOCLONAL ANTIBODIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Bristol Myers Squibb Co
  • 9.2.3 Merck & Co
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 Johnson & Johnson
  • 9.2.6 Amgen Inc
  • 9.2.7 Novartis AG
  • 9.2.8 AstraZeneca Plc
  • 9.2.9 Eli Lilly And Company
  • 9.2.10 AbbVie